1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/27214
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSegelov E.en
dc.contributor.authorTipping Smith S.en
dc.contributor.authorLam M.en
dc.contributor.authorLiow E.en
dc.contributor.authorDavies A.en
dc.contributor.authorPrenen H.en
dc.contributor.authorNguyen M.en
dc.date.accessioned2021-05-14T09:07:14Zen
dc.date.available2021-05-14T09:07:14Zen
dc.date.copyright2021en
dc.date.created20201112en
dc.date.issued2020-11-12en
dc.identifier.citationExpert Review of Gastroenterology and Hepatology. 15 (3) (pp 291-304), 2021. Date of Publication: 2021.en
dc.identifier.issn1747-4124en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/27214en
dc.description.abstractIntroduction: Colorectal cancer (CRC) is the third most common malignancy worldwide, with recent trends demonstrating increasing incidence amongst younger patients. Despite multiple treatment options, metastatic disease remains incurable. A new therapeutic strategy to harness the host immune system, specifically with immune checkpoint inhibitors, now has reported results from a number of clinical trials. Areas covered: This review will discuss in detail microsatellite instability (MSI) and other biomarkers for response to immunotherapy, summarize the pivotal clinical trials of immune checkpoint inhibitors in early-stage and metastatic MSI colorectal cancer, explore strategies to induce treatment responses in MSS CRC and highlight the emerging treatments and novel immune-based therapies under investigation. Expert opinion: Immunotherapy is now a standard of care for the proportion of CRC patients with MSI. While overall survival data are still awaited, the promise of profound and durable responses is highly anticipated. The lack of efficacy in MSS CRC is disappointing and strategies to convert these 'cold' tumors are needed. Further elucidation of optimal use of treatment sequences, combinations and novel agents will improve outcomes.Copyright © 2020 Informa UK Limited, trading as Taylor & Francis Group.en
dc.languageEnglishen
dc.languageenen
dc.publisherTaylor and Francis Ltd.en
dc.relation.ispartofExpert Review of Gastroenterology and Hepatologyen
dc.subjectcancer survivalen
dc.subjectcold stressen
dc.subject*colorectal canceren
dc.subjectdrug combinationen
dc.subjecthumanen
dc.subjectimmune systemen
dc.subject*immunotherapyen
dc.subjectincidenceen
dc.subject*mismatch repairen
dc.subjectoverall survivalen
dc.subjectreviewen
dc.subjectbiological markeren
dc.subject*cytotoxic T lymphocyte antigen 4en
dc.subject*ipilimumaben
dc.subject*nivolumaben
dc.subject*pembrolizumaben
dc.subject*microsatellite instabilityen
dc.subjectadulten
dc.subject*cancer patienten
dc.subjectcancer stagingen
dc.titleAn update on the use of immunotherapy in patients with colorectal cancer.en
dc.typeReviewen
dc.identifier.affiliationOncology-
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/17474124.2021.1845141-
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid33138649 [http://www.ncbi.nlm.nih.gov/pubmed/?term=33138649]en
dc.identifier.source2007232744en
dc.identifier.institution(Nguyen) Medical Oncology, St Vincent's Hospital Melbourne, Fitzroy, Australia (Tipping Smith, Lam, Liow, Davies, Segelov) Medical Oncology, Monash Medical Centre, Clayton, Australia (Prenen) Oncology Department, University Hospital Antwerp, Antwerp, Belgium (Segelov) Faculty of Medicine, Monash University, Clayton, Australiaen
dc.description.addressM. Nguyen, Medical Oncology, St Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia. E-mail: mikemcnguyen@gmail.comen
dc.subject.keyword*mismatch repair [m]en
dc.subject.keywordoverall survival [m]en
dc.subject.keywordreview [m]en
dc.subject.keywordimmune system [m]en
dc.subject.keywordhuman [m]en
dc.subject.keyworddrug combination [m]en
dc.subject.keyword*colorectal cancer [m]en
dc.subject.keyword*immunotherapy [m]en
dc.subject.keyword*microsatellite instability [m]en
dc.subject.keywordcancer survival [m]en
dc.subject.keywordcancer staging [m]en
dc.subject.keyword*cancer patient [m]en
dc.subject.keywordadult [m]en
dc.subject.keywordincidence [m]en
dc.subject.keywordcold stress [m]en
dc.relation.libraryurlLibKey Linken
dc.description.publicationstatusIn-Processen
dc.rights.statementCopyright 2021 Elsevier B.V., All rights reserved.en
dc.subect.keywordsColorectal cancer CTLA4 immune checkpoint inhibitor immunotherapy ipilimumab microsatellite instability mismatch repair nivolumab PDL1 pembrolizumab rectal canceren
dc.identifier.authoremailNguyen M.; mikemcnguyen@gmail.comen
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeReview-
crisitem.author.deptOncology-
crisitem.author.deptOncology-
Appears in Collections:Articles
Show simple item record

Page view(s)

12
checked on Jul 8, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.